Bevacimab 400 mg/16 ml (IV Infusion)

Indications

• Metastatic colorectal cancer treatment
• Non-squamous non-small cell lung cancer treatment
• Glioblastoma treatment
• Metastatic renal cell carcinoma treatment
• Cervical cancer treatment
• Recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer treatment

Pharmacology

• Recombinant humanized monoclonal IgG1 antibody
• Binds to and inhibits the biologic activity of vascular endothelial growth factor (VEGF)
• Approximate molecular weight of 149 kD
• Produced in a mammalian cell (Chinese Hamster Ovary) expression system

Dosage

• Treatment until disease progression or unacceptable toxicity
• Recommended doses for different types of cancer
• Specific recommended doses for different chemotherapy regimens

Administration

• Do not administer as an IV push or bolus
• Preparation for administration
• First infusion duration
• Subsequent infusion duration
• Use of appropriate aseptic technique
• Visual inspection prior to administration
• Necessary amount withdrawal and dilution
• Discard unused portion

Interaction

• Study demonstrating no significant effect of Bevacimab on the pharmacokinetics of irinotecan

Contraindications

• No contraindications listed in the manufacturer’s labeling

Side Effects

• Common adverse reactions
• Incidence and rates

Pregnancy & Lactation

• Potential fetal harm based on findings from animal studies
• No data available on bevacizumab in human milk

Precautions & Warnings

• Discontinuation indications for certain events or conditions
• Blood pressure monitoring and treatment for hypertension
• Advising females of potential risk to a fetus

Use in Special Populations

• Pediatric use safety and effectiveness
• Safety and efficacy in pediatric patients
• Geriatric use and associated severe adverse events

Overdose Effects

• Highest tested dose on humans
• Associated side effects

Therapeutic Class

• Targeted Cancer Therapy

Storage Conditions

• Refrigeration at 2-8°C
• Light sensitivity precautions
• Avoid freezing
• Keep out of reach of children

Related Brands

• Bevastim 400 mg/16 ml (IV Infusion) - beacon-pharmaceuticals-plc
• Bevixa 400 mg/16 ml (IV Infusion) - incepta-pharmaceuticals-ltd
• Bevixa 100 mg/4 ml (IV Infusion) - incepta-pharmaceuticals-ltd
• Bevacimab 100 mg/4 ml (IV Infusion) - healthcare-pharmaceuticals-ltd
• Avastin 400 mg/16 ml (IV Infusion) - roche-bangladesh-ltd